Genta Incorporated Announces Delay in Implementation of Reverse Common Stock Split

BERKELEY HEIGHTS, N.J.--(Business Wire)--
Genta Incorporated (OTCBB: GNTA.OB) announced today that a previously announced
reverse stock split will not be effective with the opening of trading on July 1,
2009. At a Special Meeting of stockholders held on June 26, 2009, Genta`s
stockholders approved a proposal to authorize the Board of Directors, in its
discretion, to effect a reverse split of Genta`s outstanding common stock at a
ratio within a specified range. On June 26, 2009, the Company announced that a
reverse stock split in a ratio of 1 for 50 would be effective with the open of
trading on July 1, 2009. A certificate of amendment has been filed with the
Delaware Secretary of State that amends Genta`s certificate of incorporation for
the reverse stock split. However, the reverse stock split, for purposes of
trading on the OTC Bulletin Board, will not be effective until a later date due
to administrative matters. The Company will announce a new effective trading
date when these matters are completed. Please refer to the preceding press
release and associated 8-K filing for further information regarding the reverse
stock split.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product
portfolio that is focused on delivering innovative products for the treatment of
patients with cancer. Two major programs anchor the Company`s research platform:
DNA/RNA-based Medicines and Small Molecules. Genasense (oblimersen sodium)
Injection is the Company's lead compound from its DNA/RNA Medicines program. The
leading drug in Genta`s Small Molecule program is Ganite (gallium nitrate
injection), which the Company is exclusively marketing in the U.S. for treatment
of symptomatic patients with cancer related hypercalcemia that is resistant to
hydration. The Company has developed G4544, an oral formulation of the active
ingredient in Ganite, that has recently entered clinical trials as a potential
treatment for diseases associated with accelerated bone loss. The Company is
also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that
is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense
are available on a "named-patient" basis in countries outside the United States.
For more information about Genta, please visit our website at: www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to
business conducted by Genta Incorporated. By their nature, forward-looking
statements and forecasts involve risks and uncertainties because they relate to
events and depend on circumstances that will occur in the future.Such
forward-looking statements include those that express plan, anticipation,
intent, contingency, goals, targets, or future developments and/or otherwise are
not statements of historical fact.The words "potentially", "anticipate",
"could", "calls for", and similar expressions also identify forward-looking
statements.The Company does not undertake to update any forward-looking
statements.Factors that could affect actual results include, without limitation,
risks associated with:

* the Company`s ability to obtain necessary regulatory approval for Genasense®
from the U.S. Food and Drug Administration ("FDA");
* the safety and efficacy of the Company`s products or product candidates;
* the Company`s assessment of its clinical trials;
* the commencement and completion of clinical trials;
* the Company`s ability to develop, manufacture, license and sell its products
or product candidates;
* the Company`s ability to enter into and successfully execute license and
collaborative agreements, if any;
* the adequacy of the Company`s capital resources and cash flow projections, the
Company`s ability to obtain sufficient financing to maintain the Company`s
planned operations, or the Company`s risk of bankruptcy;
* the adequacy of the Company`s patents and proprietary rights;
* the impact of litigation that has been brought against the Company; and
* the other risks described under Certain Risks and Uncertainties Related to the
Company`s Business, as contained in the Company`s Annual Report on Form 10-K and
Quarterly Report on Form 10-Q.

There are a number of factors that could cause actual results and developments
to differ materially.For a discussion of those risks and uncertainties, please
see the Company's Annual Report on Form 10-K for 2008 and its most recent
quarterly report on Form 10-Q.

Genta Investor Relations
908-286-3980
info@genta.com

Copyright Business Wire 2009